{"id":4549,"date":"2025-03-31T18:12:12","date_gmt":"2025-03-31T18:12:12","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/itraconazole-txt\/"},"modified":"2025-03-31T18:12:12","modified_gmt":"2025-03-31T18:12:12","slug":"itraconazole-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/itraconazole-txt\/","title":{"rendered":"itraconazole.txt"},"content":{"rendered":"

itraconazole <\/h1>\n

CLINICAL USE <\/H3>
\nAntifungal agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>100\u2013200 mg every 12\u201324 hours according to indication

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :705.6<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :99.8<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <0.03<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :10<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :20\u201340\/Unchanged

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Analgesics: possibly inhibits alfentanil metabolism\n
  • Antibacterials: metabolism accelerated by rifabutin and rifampicin \u2013 avoid with rifabutin; possibly increased rifabutin concentration \u2013 reduce rifabutin dose; clarithromycin can increase itraconazole concentration\n
  • Anticoagulants: effect of coumarins enhanced\n
  • Antidepressants: avoid concomitant use with reboxetineAntidiabetics: can enhance effects of repaglinide\n
  • Anti-epileptics: concentration reduced by carbamazepine, barbiturates and phenytoin \u2013 avoid with phenytoinAntihistamines: inhibits mizolastine metabolism \u2013 avoid concomitant use\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: possibly inhibits metabolism of aripiprazole \u2013 reduce aripiprazole dose; increased risk of ventricular arrhythmias with pimozide and sertindole \u2013 avoid concomitant use; possibly increased quetiapine concentration \u2013 reduce quetiapine dose\n
  • Antivirals: concentration possibly increased by amprenavir; concentration of indinavir increased \u2013 may need to reduce indinavir dose; with ritonavir concentration of both drugs may be increased; concentration of saquinavir possibly increased; concentration reduced by efavirenzAnxiolytics and hypnotics: concentration of buspirone, midazolam and alprazolam increased \u2013 reduce buspirone doseBosentan: possibly increased bosentan concentration\n
  • Calcium-channel blockers: negative inotropic effect possibly increased; metabolism of felodipine and possibly dihydropyridines inhibited; avoid concomitant use with lercanidipine and nisoldipineCardiac glycosides: concentration of digoxin increased\n
  • Ciclosporin: metabolism of ciclosporin inhibited (increased plasma ciclosporin levels)Cytotoxics: metabolism of busulfan inhibited, increased risk of toxicity; possibly inhibits metabolism of vincristine, increased risk of neurotoxicity; possibly increased side effects with cyclophosphamide\n
  • Diuretics: increased eplerenone levels \u2013 avoid concomitant use\n
  • Ergot alkaloids: increased risk of ergotism \u2013 avoid concomitant use5HT 1 agonists: increased eletriptan concentration \u2013 avoid concomitant useIvabradine: possibly increased ivabradine levels \u2013 reduce initial doseLipid-lowering drugs: increased risk of myopathy with atorvastatin and .iTrAConAZoLE 403simvastatin \u2013 avoid concomitant use with simvastatin, and maximum atorvastatin dose 40 mg.1Sirolimus: concentration increased by itraconazole\n
  • Tacrolimus: possibly increased tacrolimus levels\n
  • Ulcer-healing drugs: absorption reduced by histamine H2 antagonists and proton pump inhibitors\n
  • Vardenafil: possibly increased vardenafil concentration \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4>Oral,

    IV infusion <\/H4>

    Rate of Administration <\/H4>Over 60 minutes

    Comments<\/H4>Add 250 mg vial to 50 mL sodium chloride 0.9%, administer 60 mL (increased volume due to large displacement value)

    OTHER INFORMATION <\/H4>Preparations absorbed at different rates: liquid is absorbed within 2.5 hours, capsules within 2\u20135 hoursOral bioavailability of itraconazole may be lower in some patients with renal insufficiency, e.g. those receiving CAPD Janssen-Cilag advise no dose alterations required in renal impairment as drug is extensively metabolised in the liver, and pharmacokinetics are unchanged in patients with ERF compared to normal
    \n","protected":false},"excerpt":{"rendered":"

    itraconazole CLINICAL USE Antifungal agent DOSE IN NORMAL RENAL FUNCTION<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4549","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4549"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4549\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}